twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2007
vol. 109
 
Share:
Share:
abstract:
Case report

Zastosowanie przeciwciał anti-TNFα (infliximab) w leczeniu chorej z oftalmopatią tarczycową

Jan Komorowski
1
,
Joanna Jankiewicz-Wika
1
,
Agnieszka Siejka
1
,
Hanna Ławnicka
2
,
Anna Kłysik
3
,
Roman Goś
3
,
Agata Majos
4
,
Ludomir Stefańczyk
4
,
Henryk Stępień
2

  1. Department of Clinical Endocrinology , Medical University of Łódź, Poland. Head: Professor Jan Komorowski, MD, PhD
  2. Department of Clinical Immunoendocrinology , Medical University of Łódź, Poland. Head: Professor Henryk Stępień, MD, PhD
  3. Department of Clinical Ophthalmology , Medical University of Łódź, Poland. Head: Professor Roman Goś, MD, PhD
  4. Department of Radiology, Medical University of Łódź, Poland. Head: Professor Ludomir Stefańczyk, MD, PhD
Klinika Oczna 2007, 109 (4): 457-460
Online publish date: 2007/12/20
View full text Get citation
 
TNFα (tumor necrosis factor alpha) plays a central role in the development of thyroid associated ophthalmopathy (TAO). We describe and document by ophthalmic (CAS and NO SPECS scales) and radiological (MRI) evaluation a positive effect of anti-TNFα antibody (infliximab) administration on active TAO in a 58 years old woman with Graves’ disease. The single dose of infliximab administration resulted in a dramatic reduction of inflammation studies and improvement of visual function as measured by MRI and CAS and NO SPECS scales, without noticeable short-term side effects. A randomized prospective study is needed to determine whether infliximab proves to be sufficiently effective in reducing the inflammatory symptoms of TAO, and whether it can be administered safely for a prolonged period without side effects.
keywords:

TNFα, anti-TNFα, Graves’ ophthalmopathy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.